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Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) has been
used to rapidly profile the protein content of human cell lysates from MCF-10 cell and variant lines. The
method was used to study the protein profiles of these cells as they progressed from normal breast
epithelium to fully malignant cells. Distinct differences in the protein profiles were observed with
progression, and specific proteins associated with carcinogenesis (p53, c-myc, and c-erbB-2) were heavily
expressed in these cells as detected by MALDI-TOFMS. These proteins were also isolated using non-porous
reversed-phase high performance liquid chromatography (NP-RP-HPLC) and mass analyzed by MALDI-
TOFMS to provide molecular weight information without interference from other proteins in the whole cell
lysates, and to avoid suppression effects in mixtures of proteins detected by MALDI-TOFMS. In order to
confirm the identity of these oncoproteins, the cell lysates were subjected to one-dimensional (1-D) gel
separation and subsequently electroblotted onto a poly(vinylidene difluoride) (PVDF) membrane for
further analysis. Trypsin and cyanogen bromide digestions were performed on these proteins eluted from
excised PVDF bands which were then analyzed by MALDI-TOFMS. The identity of these proteins was
confirmed by database matching procedures.# 1998 John Wiley & Sons, Ltd.
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An important area in clinical oncology is the analysis of the
expression of oncoproteins in the cell. A potentially
powerful tool for rapidly screening for the presence of
these oncoproteins in complex biological matrices such as
cell lysates is matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOFMS). In
previous work, MALDI-TOFMS has been used to rapidly
differentiate and identify bacteria1–15 based on the analysis
of the protein profiles of bacterial whole cell lysates
employing a simple sonication1 or freeze-thaw method.10
Alternatively, several groups have demonstrated the use of
MALDI to analyze intact bacterial cells and were able to
identify the bacteria based on the observed protein spectral
patterns.2,3,13 In this work, relatively simple sample
preparation methods were used which generally limited
the observed MALDI-MS to water-soluble proteins under
20 kDa. In more recent work, much more extensive
solubilizing procedures have been used such that large
proteins up to several hundred kilodaltons (kDa) have been
observed fromE. coli samples using MALDI-TOFMS of
whole cell lysates. This method8 was used to monitor the
induction or repression of expressed proteins in the mass
range of 25 to 70 kDa which resulted in response toL-
arabinose catabolism. In related work, an extensive
solubilizing procedure has been used with MALDI-MS
detection for the study of the protein patterns in mammalian
cells and culture supernatants16 and, more recently, protein
profiling of human cerebrospinal fluid has been per-
formed.17
Oncogenes are mutated forms of normal genes that
participate in the control of cellular proliferation and/or
differentiation. Oncogenes implicated in breast carcinoma
by experimental and clinical studies include c-erbB-2, H-
ras, c-myc, int-1, and int-2.18 Tumor suppressor genes are
defined as genes that contribute to carcinogenesis by
deletion, reduced expression, or inactivation. Strong
evidence for the involvement of p53, a tumor suppressor
gene in carcinogenesis, has come from studies of cell-cycle
regulation.19 While the features of p53 are complex and
reviewed extensively elsewhere,20,21it should be noted that
the loss of heterozygosity and/or mutation has been
confirmed in a variety of tumor types,22 and especially in
breast carcinoma.23–26Oncoproteins, encoded by oncogenes
and tumor suppressor genes, are crucial in the control of
both normal and aberrant growth as they regulate a series of
complex signal transduction pathways. When these path-
ways become deregulated, uncontrollable cell proliferation
often results. The ability to rapidly detect and monitor
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abnormalities in oncoprotein expressionmay increaseour
understanding of thebasic biologicalprocessesinstrumental
in tumor disease,and may also result in new methodsfor
diagnosisandtreatmentof patientswith cancer.
In this work, we describe a method for lysing of
mammalian cells and for solubilizing the high molecular
weightprotein contentof thecells.Thesamplepreparation
procedure developedfor MALDI -TOFMS analysisallows
for detectionof proteins(>100kDa)from human wholecell
lysates.Thehumancellsusedrepresent thevariousstagesof
development in the MCF-10 cell line. This cell line was
originated by spontaneous immortalization of breast
epithelial cells obtained from a patient with fibrocystic
disease.28 UsingMALDI -TOFMSto analyzetheseMCF-10
cells may resultin the identification of breastcancer genes
involved in sporadic breast cancer. Because all lines
constituting the full spectrumof progression from normal
to malignant werederivedfrom a single patient, irrelevant
differencesin geneexpressionshould be minimal.
Thegoalsof this work includeusing MALDI-TOFMS to
study the expression of proteins in malignant cells not
readily observed in normal cells or the higher levels of
specific proteins present in malignant cells. MALDI -
TOFMS analysis of the whole cell lysates of these MCF-
10 cells results in thedetection of several oncoproteins that
have been implicated in breast carcinoma which can be
readily identified including H-ras, c-myc, int-2,18 and
p53.22–27 The known molecular weightsof theseoncopro-
teins from the Swiss-Protein Database were utilized as a
guide to distinguish MALDI protein profiles originating
from the malignant compared to the normal breast
epithelium cell lysates.Fractioncollection from non-porous
reversed-phase high performance liquid chromatography
(NP-RP-HPLC) of some of the proteinpeaksof the tumor
whole cell lysate was also performed. The collected
fractionswereanalyzedusing MAL DI-TOFMSto ascertain
their molecular weights and to observe the expressed
proteins without interferencefrom suppressioneffects in
the MALDI process. The protein profiles were also
compared to the expressed bands of similar molecular
weight observedin 1-D gels.The proteins on the 1-D gels
were subsequently electroblotted onto poly(vinylidene
difluoride) (PVDF) membranes, bands of interest were
excisedfrom thePVDFmembraneandproteinswereeluted
off the bands.This wasperformedin order to identify the
expressed bands using MALDI-TOFMS. Trypsin and
cyanogen bromide digests were also performed on the
elutedproteinsandtheresultingpeptides from eachprotein
wereagain examined by MALDI for protein identification
andconfirmation.The resultingpeptideswere compared to
those found in the MS-Digest of the Protein Prospector
Database.However, at thispointnodetailedsequencinghas
been performed on these proteins. Nevertheless, it is
demonstrated that MALDI -TOFMS may indeed be a
powerful analytical tool for applications involving identi-
fication and monitoring of oncoproteins as well as




The chemicals involved in this study were usedwithout
prior purification. Acetone (HPLC grade) was obtained
from Fisher(Fair Lawn, NJ, USA). Acetonitrile, guanidine
hydrochloride (gu-HCl), a-cyano-4-hydroxycinnamic acid
(a-CHCA) andphenylmethylsulfonyl fluoride(PMSF)were
from Sigma (St. Louis, MO, USA), andTriton X-100 was
from ICN (Aurora,OH,USA).Thenitrocellulose(NC) used
was Immobilon-NC Pure from Mill ipore (Bedford, MA,
USA). Trifluoroacetic acid (TFA) and cyanogen bromide
(CNBr) were purchasedfrom Aldrich (Milwaukee, WI,
USA). Trypsin wasacquired from Promega(Madison, WI,
USA). Distilled and deionized water was obtained from a
Mili -Q reagentgrade purification systemfrom Mill ipore
(Bedford, MA, USA).
Cell cultures
The MCF-10 cell samples used in these experiments
originated by spontaneous immortalization of breast
epithelial cellsfrom afibrocysticpatient.28 Fully malignant,
metastatic variants, MCF-10 Cala, were also derived.29
Cells were maintained in a humidified CO2 incubator at
37°C, andadherentcellsharvestedin log phase(75–80%
confluence).In orderto harvestthecells, thegrowth media
wasaspiratedandthecellsgentlywashedwith PBS,prior to
scraping with a rubber policeman. The cells wereimmedi-
ately frozen(ÿ80°C) uponremovalfrom the tissueculture
dishes.
1-D SDS-PAGE and PVDF electroblotting
Frozen cell pellets were directly solubilized in sodium
dodecyl sulfate-polyacylamide gel electrophores (SDS-
PAGE) samplebuffer underreducingconditions.Samples
were boiled for 5 min, andaftercooling, separatedon 10%
acrylamide gels. After SDS-PAGE separation, proteins
were electrophoretically transferredto a PVDF membrane
(Micron SeparationsInc., West Borough, MA, USA) in
transfer buffer (25 mM Tris-HCl/192 mM glycine, 20%
methanol, pH 8.2) for 1.5 h at 13 V/cm. The proteinswere
visualized by staining with Coomassieblue after being
transferredonto the PVDF membrane.
Matr ix, substrate and sample preparation
a-CHCA wasthekeymatrixusedin theseexperiments.The
matrix waspreparedasa saturatedsolution in a 4:1 ratio of
acetone to Mili -Q water containing 0.5% TFA. Before
applying thesamplesolutionto thesteelprobetip, 2 mL of
NC wereapplied to thetip andallowedto dry followedby 4
L of sample solution, which was also allowed to dry.
Subsequently,4 mL of CHCA matrixsolution wereaddedto
the probetip andalso allowed to dry.
Prior to lysis, thecell pelletswerewashedoncewith cold
10 mM Tris-HCl buffer and 150 mM NaCl (pH 7.5) via
centrifugation for 3 min at 1000g. Thecellswerelysed by
resuspension in 0.2 mL of 10 mM Tris-HCl buffer (pH
7.4), 6 M gu-HCl and10to 20%Triton X-100. Thismixture
was vortexed for at least 30 s, and stored at ÿ20°C
overnight. Subsequently, the lysate was fractionated by
centrifugation in anEppendorfcentrifugeat 15000g for 20
minutes.After theaddition of 20 mL of 1.0 mM PMSF, the
soluble portionwasstoredatÿ20°C until MALDI analysis
wasperformed.
Selectedprotein bandsfrom the PVDF membranewere
cut andplaced in Eppendorftubes. In order to removethe
Coomassie bluestainfrom thebands,a de-staining solution
consisting of 20% methanol, 10% acetic acid, and 70%
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Figure 1. MALDI-TOF massspectraof (a) malignantand(b) normalbreastcell lysatesfrom MCF-10cell line.
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Mili -Q waterwasemployed. Thetubesweregentlyshaken,
and allowed to sit for 10–20 min. After decanting the
solution, the bandswere rinsedwith Mili -Q water before
being treatedwith theelutionsolution.Theelutionsolution
waspreparedwith 2%SDS,10%Triton X-100,and50mM
Tris-HCl (pH 9–9.5).Thiswasfollowedby centrifugation at
14 000g for 20 min.
Trypsin digestion(1 mg/mL) wasperformedontheeluted
proteins from the excised PVDF bands. An enzyme/
substrate ratio of 1:50 was used. These mixtures were
incubatedat 37°C for 24 hr. A CNBr digestion (0.15M in
70%formic acid) wasalsoperformedon theelutedproteins
at room temperature(25°C) in the dark for 24 h.
NP-RP-HPLC analysis
A Beckman(Fullerton, CA, USA) SystemGold1 HPLC
was used for this work. It has a programmable solvent
delivery module with a dual-pump (Model 127). This
module includes a System Control Center display and
keypad which permits control of the pump and external
modules directly. The detector employed was a program-
mable detector module (Model 166)with adeuteriumlamp.
All separationsweremonitoredat 214nm.Thecolumnwas
purchased from MICRA (Northbrook, IL, USA). It
containednon-porousC18 packing materialwith a 1.5 mm
particle diameter. The dimension of the column was
4.6 33 mm where the wide-bore column was necessary
to collect an adequate amount of material and the short
length allowed for rapid separations in minutes. The RP-
HPLC separation of proteins in the tumor cell lysatewas
performed via gradient elution of two solvents (solventA:
Mili -Q waterwith 0.1% TFA; solvent B: acetonitrile with
0.1% TFA) with a flow rate of 1 mL/min where the
temperatureof the non-porous column was maintained at
60°C in a Timberline (Boulder,CO, USA) column heater.
The gradientprofile for solvent B was as follows: 0%, 1
min; 0–20%,2 min; 20–60%, 8 min; 60–100%, 2 min; and
100–0%, 1 min. The fractionscollected weresubsequently
subjectedto MALDI -TOF massspectral analysis.
MA LDI-TOF massspectral analysis
TheTOF mass spectrometeremployed in these studieswas
a modified Wiley-McLaren design with a four-plate
acceleration structure.30 It was capable of high voltage
accelerationup to 20kV (R.M. JordanCo.,GrassValley,
CA, USA). Thelaser source usedto produce MALDI wasa
Continuum Minilite 10 Hz Nd:YAG laser system (Con-
tinuum, Santa Clara, CA, USA). The laser beam was
focusedontotheprobetip ata45° angleto theprobesurface
with a single 12.5 in f.l. quartz lens to spot a size of
0.2 0.5 mm. The resulting power density at this spot
was estimated at 5 106 to 1 107 W/cm2 at 355 nm
radiation in theseexperiments. The detector was a triple
microchannel plate (MCP) detector (R.M. Jordan Co.)
which adapted a CuBe conversion dynode with post-
acceleration (PA) capability up to 12 kV31 in front of
theMCP. The total ion accelerationacrosstheTOF device
may thusbe>30 kV. Thepost-aceleration stageenhances
the efficiency for detectionof heavy species, but at the
expense of resolution. The voltages were similar for all
experiments,asfollows: repeller at15 kV, extractorplate
1 at 10 to 12 kV, extractorplate 2 at 3 to 5 kV,
extractorplate3 wasgrounded,andPA atÿ10 toÿ13 kV.
The 1 m long TOF tubewaspumped to a basepressureof
2 10ÿ7 Torr. DatawasrecordedusingaLeCroy 9310AM
digital oscilloscope (LeCroy Corp., Chestnut Ridge, NY,
USA) and was processed on a Gateway 586 166 MHz
computer. Pulsed delay extraction (PDE) as described in
previouswork32 wasusedfor the trypsin andCNBr digest
analyses.PDE wasperformedusing a simplehigh voltage
transistor switch constructed as described in previous
work.32 The switch provideda 0–3 kV voltagepulsewith
a 75 ns fall time.
Utilizing known molecular weights of the detected
oncoproteins from the Swiss-Protein Databaseat http://
www.expasy.ch/sprot/ as a guide, protein peaksfrom the
MALDI profilesof thetumorandnormalwholecell lysates
were identified.The wholecell lysates werethensubjected
to NP-RP-HPLC to isolate theseproteinsto further verify
their identity by sizingthecollected fractionswith MAL DI.
Trypsin and CNBr digestswere performedon the eluted
proteins from the excisedPVDF bandsand the resulting
peptides from each protein were again examined via
MALDI for peptide identification and confirmation. The
observed molecular weights of peptideswerecomparedto




themalignantandnormal wholecell lysatesof theMCF-10
cell lines. The MALDI massspectrum (Fig. 1(a)) of the
malignantbreastcell lysate is dominatedby several protein
peaks. In contrast, the MALDI mass spectrum of the cell
lysate of a normal cell line showsvery few protein peaks
standing out abovethe backgroundasshownin Fig. 1(b).
Thedifferencesbetweenthemassspectramaybeexplained
by high expression of certainproteinsin themalignantcell
line butnot in thenormal cell line. Theestimatedmolecular









P01112 TransformingproteinH-ras-1(c-H-Ras) 21 298 21 000 21 930 22 210
P11487 Int-2 proto-oncogeneproteinprecursor(int-2) 26 886 27 000 26 390 26 310
P04637 NuclearPhosphoprotein (p53) 43 653 44 000 43 680 44 350
P01106 MYC Proto-oncogeneprotein(c-myc) 48 804 49 000 49 060 49 040
P37243 Thyroid hormonereceptor beta-2(THR beta-2)a 54 356 55 000 54 460 54 180
P04626 ErbB-2 receptor protein-tyrosinekinaseprecursor(c-erbB-2) 137911 140000 141110b 141110
a This protein washighly expressedin 1-D gel andalsoappearedquite consistentlyin MALDI massspectra.
b The molecularweightof this protein(c-erbB-2)wascalculateddirectly from the MALDI whole cell lysatemassspectra.
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Figure 2. MALDI-TOF massspectraof proteinfractionscollectedfrom NP-RP-HPLCof (a) p53and(b) THR beta-2.
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weights corresponding to several of these peaks are
tabulated in Table 1, with the possible identities of these
proteinsbasedon their molecular weights.
In orderto moreclearly distinguishandidentify eachof
thesemajorpeaks, thewholecell lysates wereseparatedby
NP-RP-HPLCandtheseparatedproteinfractionscollected.
The fractions were then analyzedby MAL DI-TOFMS to
further verify the molecular weights of thesekey peaks.
Figures2(a)and(b) showtheMAL DI massspectraof some
of the protein fractions collected from the NP-RP-HPLC
separation. In Fig. 2(a) the ion peakis detectedaround 43
680Da,which coincideswith thep53protein, while in Fig.
2(b) theproteinfractioncollectedhasamolecular weightof
54 460 Da which would correspond to thyroid hormone
receptor beta-2 (THR beta-2) protein. In addition, other
fractionswerecollected andsizedby MALDI where peaks
were observed at 21 930 and 26 390 Da which probably
correspond to c-H-rasandint-2 proteins, respectively. The
molecular weightsobtainedby MAL DI-TOFMSof NP-RP-
HPLC separatedproteinsarealsotabulatedin Table1.
To confirm theresultsof Figs1 and2, andto identify the
highly expressed tumor proteins, 1-D SDS-PAGE separa-
tionsof thesecell lysates(notshown)wereperformedwhich
weresubsequently electroblottedonto a PVDF membrane.
Several proteins aredefinitely more heavilyexpressedthan
other proteins in the malignant lysateSDS-PAGE separa-
tion, andcorrespond in molecularweight to the expressed
proteins observedon MALDI-TOFMS of the samelysate.
Due to gel-to-gel variation observed in the 1-D gel
separation, the molecular weights were averaged from
severalgels,as shownin Table 1. The molecular weights
observed by direct MALDI -MS (averaged from several
mass spectra), MAL DI-MS of NP-RP-HPLC separated
fractions and1-D gel separations are fairly consistentand
aresimilar to thoseof the SwissProteindatabasefor these
cancer-related proteins. The differences in molecular
weights may be dueto variousmodifications andsubstitu-
tions that may be present, but arenot able to be identified
without more extensive MS analysisor sequencing.
In orderto furtherverify theidentity of theoverexpressed
proteins, trypsin and CNBr digestionswere performed on
the proteins eluted from the excised PVDF bandsof the
whole cell lysates. A MALDI massspectrum of a CNBr
digestof oneof theproteinsis shown in Fig.3.Theresulting
peaksdetectedin MALDI-TOFMS aretabulatedin Table2
and were comparable to the databaseCNBr digestof p53
protein. Similarly tryptic digestionwas performedon this
protein from the PVDF membraneto ascertainits identity.
The peptides detectedby MALDI-MS are compared to
those from thedatabasein Table 3. Both digestionmethods
and the molecular weights obtained appear to verify the
identity of this protein as p53. CNBr and tryptic digests
were also performed on the 49 and 55 kDa proteins for
analysis. The digestion products were compared to the
database and appeared to confirm the identity of these
proteinsasc-mycandTHR beta-2respectively (seeTables
4–7).
Al thoughwedid notactualy sequencetheproteinsin this
work, theMALDI analysisprovidedsufficient dataregard-
ing theidentity of key expressed oncoproteins.Sincethis is
a preliminary study, a continuation of this work will entail
rigoroussequencing along with the investigation of gene-
proteinexpressionandvariation in thesecell lysates.Forthe
current work, the detection of p53, c-erbB-2, c-myc and
Figure 3. PDE-MALDI-TOF massspectrumof CNBr digestof proteinelutedfrom PVDF band.Probablecandidate:p53.
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THR beta-2 in the tumor whole cell lysate (Fig. 1(a))
coincides with the expressionof proteins on the PVDF
membrane.It is generally believed thatc-erbB-2 amplifica-
tion/overexpressionin breastcancer identifies a subset of
patients with poor prognosis tumors.33 Even though the
prognosticvalueof p53immunohistochemical expressionin
breast cancer is still controversial,34 many reports have
shown thatp53overexpressionmaybeanindicatorof poor
prognosisin breast cancer.35,36A recentstudyalsosuggests
that p53andc-erbB-2oncoproteinscould beconsideredas
biomarkers of the biological aggressivenes of breast
carcinoma, but their significance in the evaluation of the
response to treatment and survival time seems to be
limit ed.37 In otherstudies,c-myc andanother oncoprotein
(bcl-2) mayplay rolesin thecontrol of cellularandnuclear
trafficking of p53 since they were detected mainly at the
outer nuclearmembranein thecell andtheir levelsandthat
of nuclearp53 are inversely correlated.38,39 Amplification
andelevation of c-myc in breast carcinomasalsoappear to
beanindependentprognosticmarkerof overallsurvival.40 It
shouldbenoted thatc-myc-inducedcellular transformation,
as opposed to a number of other oncogenes,results from
alternately high expression of a normal coding sequence
ratherthanactivationby apointmutation, asoccurswith ras
for example.Nonetheless,thefull oncogenic potentialof c-
myc involves cooperation with other oncogenessuch as
ras.41
The rapid screening and detection of oncoproteins in
humancells remain important problems. There are many
potentialgeneticabnormalities that may result in a normal
breastcell transforminginto a cancercell. Thus,onemight
expectdifferences in protein expressionin different tumors
dependingon the particular mechanism at work. Never-
theless,oncogene overexpression would be expectedin
breasttumor formation,andtheoncogenesexpressedshould
be related to the type of tumor and its mechanismfor
carcinogenesis. Moreover, in each case there may be
mutatedgenesthatexpressvariantsof oncoproteinsso that
methodsfor rapidly screeningandidentifying theseproteins
Table 2. CNBr digestof an overexpressedprotein from the 1-D gel




Sequence:Start-End DatabaseMH (average) MALDI MH
41–66 2 973.2 2 957
134–169 4 200.9 4 209
1–40 4 434.9 4 425
170–246 9 087.2 8 935
41–133 9 809.0 9 574
161–243 9 961.1 10 026
45–160 12 461.2 12 427
247–384 15 707.8 15 501
Table 3. Trypsin digestof an overexpressedprotein from the 1-D




Sequence:START - END DatabaseMH (average) MALDI MH
176–196 2 511.8 2 591
1–24 2 688.9 2 678
133–158 3 074.7 3 069
66–110 4 506.1 4 339
214–267 6 144.0 5 989
210–267 6 678.6 6 683
1–65 7 402.1 7 472
Table 4. CNBr digestof an overexpressedprotein from the 1-D gel




Sequence:Start-End DatabaseMH (average) MALDI MH
446–476 3 686.4 3 672
308–349 5 003.8 5 054
395–445 6 245.2 6 075
374–438 7 678.8 7 762
190–307 13 386.3 12 446
70–189 14 663.8 14 724
Table 5. CNBr digestof an overexpressedprotein from the 1-D gel




Sequence:Start-End DatabaseMH (average) MALDI MH
1–134 15 423.0 15 224
135–439 34 112.0 36 228
Table 6. Trypsin digestof an overexpressedprotein from the 1-D




Sequence:Start-End DatabaseMH (average) MALDI MH
119–128 1 223.4 1 215
445–458 1 706.1 1 698
149–165 2 068.4 2 060
298–321 2 952.6 2 973
305–331 3 415.3 3 424
74–109 4 234.6 4 245
217–255 4 455.9 4 567
358–409 5 556.4 5 579
354–406 5 628.4 5 785
1–71 8 307.1 8 176
Table 7. Trypsin digestof an overexpressedprotein from the 1-D




Sequence:Start-End DatabaseMH (average) MALDI MH
52–65 1 582.9 1 584
341–355 1 752.9 1 758
66–83 2 012.3 2 016
299–317 2 262.5 2 281
276–299 2 469.8 2 402
399–421 2 621.0 2 622
127–156 3 344.9 3 210
11–51 5 123.4 5 055
67–143 8 344.3 8 295
167–269 11 041.7 10 747
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aresorelyneeded. Evenmore essentialis thecapability for
monitoring subtle changes in protein expression as cells
mutate from normal to pre-neoplasticto malignantpheno-
types. It seemsreasonablethat changes in protein expres-
sionmay be related to the cancerprocess.
In thisinitial work, MALDI-TOFMSof wholecell lysates
or MALDI-TO FMS of protein fractionsseparatedby NP-
RP-HPLCfrom whole cell lysateshasbeenshownto be a
powerful methodfor rapidly profiling expressedoncopro-
teins in tumor cells. This methodmay proveimportantfor
understanding mechanisticstudiesof gene-protein expres-
sion in human carcinomas. More significantly though,
MALDI-TOFMS may prove to be an importantanalytical
tool for detection andprofiling of oncoproteinsin different
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